Price to FCFE (P/FCFE)
Paying user area
Try for free
Danaher Corp. pages available for free this week:
- Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Solvency Ratios
- Analysis of Reportable Segments
- Enterprise Value (EV)
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2005
- Price to Earnings (P/E) since 2005
- Price to Operating Profit (P/OP) since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Danaher Corp. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Free Cash Flow to Equity (FCFE)
Danaher Corp., FCFE calculation
US$ in millions
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
The financial information reveals fluctuations in both net cash provided by operating activities and free cash flow to equity (FCFE) over the five-year period. Operating cash flow demonstrates a moderate initial increase followed by a decline, while FCFE exhibits a more pronounced pattern of volatility.
- Net Cash from Operations
- Net cash provided by operating activities increased from US$8,358 million in 2021 to US$8,519 million in 2022, representing a modest growth rate. However, a subsequent decrease is observed, falling to US$6,490 million in 2023. This trend partially reverses in 2024, with a rise to US$6,688 million, but then declines again to US$6,416 million in 2025. Overall, operating cash flow demonstrates a generally decreasing trend when comparing the beginning and end of the period.
- Free Cash Flow to Equity (FCFE)
- FCFE experienced a significant decrease from US$9,044 million in 2021 to US$5,688 million in 2022. This downward trend continues into 2023, with FCFE reaching US$3,493 million. A slight increase is noted in 2024, to US$3,640 million, but the most substantial change occurs in 2025, where FCFE rises considerably to US$6,338 million. The FCFE trajectory indicates substantial volatility, with a recovery towards levels seen earlier in the period in the final year.
The divergence between operating cash flow and FCFE suggests that factors beyond core operations, such as financing activities or investment decisions, are significantly influencing the cash available to equity holders. The substantial increase in FCFE in 2025, despite relatively stable operating cash flow, warrants further investigation to understand the underlying drivers of this change.
The observed patterns indicate a period of fluctuating cash generation for equity holders, with a notable recovery in the most recent year. Continued monitoring of these trends, alongside a deeper analysis of the components of FCFE, is recommended.
Price to FCFE Ratio, Current
Danaher Corp., current P/FCFE calculation, comparison to benchmarks
| No. shares of common stock outstanding | |
| Selected Financial Data (US$) | |
| Free cash flow to equity (FCFE) (in millions) | |
| FCFE per share | |
| Current share price (P) | |
| Valuation Ratio | |
| P/FCFE | |
| Benchmarks | |
| P/FCFE, Competitors1 | |
| AbbVie Inc. | |
| Amgen Inc. | |
| Bristol-Myers Squibb Co. | |
| Eli Lilly & Co. | |
| Gilead Sciences Inc. | |
| Johnson & Johnson | |
| Merck & Co. Inc. | |
| Pfizer Inc. | |
| Regeneron Pharmaceuticals Inc. | |
| Thermo Fisher Scientific Inc. | |
| Vertex Pharmaceuticals Inc. | |
| P/FCFE, Sector | |
| Pharmaceuticals, Biotechnology & Life Sciences | |
| P/FCFE, Industry | |
| Health Care | |
Based on: 10-K (reporting date: 2025-12-31).
1 Click competitor name to see calculations.
If the company P/FCFE is lower then the P/FCFE of benchmark then company is relatively undervalued.
Otherwise, if the company P/FCFE is higher then the P/FCFE of benchmark then company is relatively overvalued.
Price to FCFE Ratio, Historical
Danaher Corp., historical P/FCFE calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | ||||||
| Selected Financial Data (US$) | ||||||
| Free cash flow to equity (FCFE) (in millions)2 | ||||||
| FCFE per share3 | ||||||
| Share price1, 4 | ||||||
| Valuation Ratio | ||||||
| P/FCFE5 | ||||||
| Benchmarks | ||||||
| P/FCFE, Competitors6 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| P/FCFE, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| P/FCFE, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Data adjusted for splits and stock dividends.
3 2025 Calculation
FCFE per share = FCFE ÷ No. shares of common stock outstanding
= ÷ =
4 Closing price as at the filing date of Danaher Corp. Annual Report.
5 2025 Calculation
P/FCFE = Share price ÷ FCFE per share
= ÷ =
6 Click competitor name to see calculations.
The Price to Free Cash Flow to Equity (P/FCFE) ratio exhibits considerable fluctuation over the observed period. Initially, the ratio increased significantly before declining, suggesting shifts in investor sentiment and valuation relative to the company’s free cash flow generation.
- Share Price
- The share price experienced a decrease from $262.39 in 2021 to $250.11 in 2022, followed by a slight increase to $250.65 in 2023. A more substantial decline occurred in 2024, reaching $207.95, with a modest recovery to $209.19 in 2025. This indicates overall downward pressure on the stock price during the latter part of the period.
- FCFE per Share
- Free Cash Flow to Equity per share decreased notably from $12.64 in 2021 to $7.81 in 2022. This downward trend continued to $4.72 in 2023, representing the lowest value within the observed timeframe. A slight recovery to $5.09 occurred in 2024, followed by a more pronounced increase to $8.96 in 2025. This suggests improving cash flow generation towards the end of the period.
- P/FCFE Ratio
- The P/FCFE ratio increased from 20.75 in 2021 to 32.04 in 2022, coinciding with the decrease in FCFE per share. The ratio peaked at 53.08 in 2023, reflecting a significant premium investors were willing to pay for each dollar of FCFE. A decrease to 40.83 in 2024 was observed, followed by a substantial decline to 23.34 in 2025. This final decrease aligns with the increasing FCFE per share and the relatively stable share price, indicating a more reasonable valuation.
The observed pattern suggests that investor valuation, as reflected in the P/FCFE ratio, was initially increasing despite declining FCFE. However, as FCFE began to recover in 2024 and 2025, the P/FCFE ratio decreased, potentially indicating a correction in valuation or a shift in investor expectations. The volatility in the P/FCFE ratio warrants further investigation into the underlying drivers of both the share price and FCFE.